These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2126736)

  • 1. Clinical profile of a new non-steroidal antiandrogen.
    Mahler C; Denis L
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):921-4. PubMed ID: 2126736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
    Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring of erection function in patients with prostatic carcinoma treated with Casodex].
    Migliari R; Muscas G; Melis M; Garau M; Sorgia M; Scarpa RM; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):155-61. PubMed ID: 1830408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    Eur Urol; 1994; 26(3):219-26. PubMed ID: 7528662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
    Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
    Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer.
    Migliari R; Muscas G; Usai E
    J Urol; 1992 Aug; 148(2 Pt 1):338-41. PubMed ID: 1378907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia.
    Eri LM; Haug E; Tveter KJ
    Br J Urol; 1995 Mar; 75(3):335-40. PubMed ID: 7537602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).
    Freeman SN; Mainwaring WI; Furr BJ
    Br J Cancer; 1989 Nov; 60(5):664-8. PubMed ID: 2803943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.
    Lunglmayr G
    Horm Res; 1989; 32 Suppl 1():77-81. PubMed ID: 2515147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
    Blackledge GR
    Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the adult male rat.
    Chandolia RK; Weinbauer GF; Simoni M; Behre HM; Nieschlag E
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):547-55. PubMed ID: 1759544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
    Maucher A; von Angerer E
    J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
    Kennealey GT; Furr BJ
    Urol Clin North Am; 1991 Feb; 18(1):99-110. PubMed ID: 1992575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer].
    Kotake T; Usami M; Isaka S; Shimazaki J; Oishi K; Yoshida O; Ozono S; Okajima E; Kanetake H; Saitoh Y; Tsukagoshi S; Akaza H; Koiso K; Kameyama S; Honma Y; Aso Y; Nakano E; Okuyama A; Naito S; Kumazawa J; Niitani H; Taguchi T
    Hinyokika Kiyo; 1996 Feb; 42(2):143-53. PubMed ID: 8712091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
    Tyrrell CJ
    Eur Urol; 1994; 26 Suppl 1():15-9. PubMed ID: 7537664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal.
    Motofei IG; Rowland DL; Popa F; Kreienkamp D; Paunica S
    BJU Int; 2011 Jul; 108(1):110-5. PubMed ID: 20955264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C; Verhelst J; Denis L
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
    Blackledge GR; Cockshott ID; Furr BJ
    Eur Urol; 1997; 31 Suppl 2():30-9. PubMed ID: 9074908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.